- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03285191
Subject Insights to Understand Rheumatoid Arthritis (RA)
August 14, 2018 updated by: GlaxoSmithKline
Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting the joints and can lead to joint pain, swelling, redness and stiffness and can cause deformity, loss of strength and immobility.
This cross-sectional qualitative study aims to explore the burden of established RA by conducting semi-structured Concept elicitation (CE) interviews (60 minutes duration) and real-time data capture task.
The conceptual model developed from this data will be used to support the development of GSK3196165, a recombinant human monoclonal antibody (mAb) targeted for the treatment of RA.
The CE interviews will explore the subject experience of RA and will collect information about symptoms, disease impact on functioning and health related quality of life (HRQoL), and treatment experiences/impacts of the condition and the language used by subjects to describe them.
Following the CE interview, subjects will be asked to complete a brief symptom ranking exercise where they will need to rank how bothersome each RA symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
After the interviews, the real-time disease experience of subjects will be captured by the real-time data capture app-based activity over a period of 7 days.
Approximately 30 English-speaking subjects from the United States (US) with RA who are inadequate responders of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and/or (bDMARDs) will participate in the interviews and of these, 10 subjects will be offered the opportunity to participate in the real-time data capture sub study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cheshire
-
Bollington, Cheshire, United Kingdom, SK10 5JB
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Thirty English speaking subjects from the US with RA who are inadequate responders to csDMARDs and/or bDMARDs will be included in this study.
Description
Inclusion Criteria:
- Male or female, aged >=18 years or over.
- Subject has a diagnosis of rheumatoid arthritis and has had this diagnosis for at least 6 months.
- Subject has a minimum of four swollen and tender joints.
- Subject is either an inadequate responder to csDMARDs and has never received a bDMARD or an inadequate responder to bDMARDs (subject may be receiving bDMARDs only or may be continuing csDMARD treatment in addition to receiving a bDMARD).
- Subject is willing and able to participate in the study and provide written informed consent.
- Subject is a fluent US-English speaker and is able to read, write and fully understand the US-English language.
- Subject is willing and able to participate in a 60-minute interview and optional app task to discuss their experience of rheumatoid arthritis.
For subjects taking part in real-time data capture:
- Subject owns/or has access to either a smartphone [iPhone Operating System (iOS) or android] or tablet which has video, audio/microphone and photographic capabilities and access to either the Apple app store or Google play store to download the app.
- Subject is willing and able to take part in the real time data application task and respond to a series of questions/tasks fielded via the application over the course of seven days and is willing to respond to some brief questions following the real-time data capture task about their experience of using the app and completing the tasks, in a 5-10 minute telephone call.
- Subject would feel comfortable recording short videos of themselves and providing audio commentary in response to app questions/tasks.
Exclusion Criteria:
- Subject has a history of other inflammatory rheumatological or autoimmune disorders that are not secondary to RA.
- Subject has significant unstable or uncontrolled acute or chronic disease other than RA.
- Subject is unwilling or unable to comply with the requirements of the study or has a physical or mental condition that, in the opinion of the physician, may affect the subject's ability to participate in the study, the responses he/she might provide or their ability to provide consent.
- Subject is currently or has previously been enrolled in a clinical trial for RA in the past year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subjects participating in the CE interview
Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
|
Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
|
Subjects participating in interview and real-time data capture
Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
|
Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device.
Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with RA participating in CE interviews
Time Frame: 1 day
|
CE interviews will be carried out to explore disease experience with respect to symptoms, impacts and treatment/surgical experiences.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of RA experience by using real-time data data capture task
Time Frame: Up to 7 days
|
A subgroup of ten of the thirty subjects participating in the CE interviews will be asked to take part in the real-time data capture task over the course of 7 days and during this time a series of 5-7 questions/tasks will be asked to subjects via the application to explore the experience of the symptoms, HRQoL impacts, treatment of RA and any day-to-day variability that exists in real time'.
|
Up to 7 days
|
Preparation of the conceptual model
Time Frame: Up to 7 days
|
Data obtained from the CE interviews and real-time data capture as well as literature reviews will be used to develop a conceptual model for RA.
Symptom, impact, and treatment concepts which have been identified will be grouped into domains and displayed visually and any identified relationships or trends between domains will also be included in the model.
A contents key will be developed to show the source of the concept.
|
Up to 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 3, 2017
Primary Completion (Actual)
August 17, 2017
Study Completion (Actual)
August 17, 2017
Study Registration Dates
First Submitted
June 29, 2017
First Submitted That Met QC Criteria
September 12, 2017
First Posted (Actual)
September 15, 2017
Study Record Updates
Last Update Posted (Actual)
August 15, 2018
Last Update Submitted That Met QC Criteria
August 14, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 206577
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Numerical rating scale
-
University Hospital, RouenCompletedPain | Cystic FibrosisFrance
-
Jessa HospitalCompletedScar | Minimally Invasive Cardiac SurgeryBelgium
-
Istanbul Medipol University HospitalCompletedPain | Dental PainTurkey
-
University of FlorenceCompletedPostoperative Pain | Retinal Detachment
-
Rambam Health Care CampusUnknownStress Disorders, Post-Traumatic | Depressive Disorder, MajorIsrael
-
Taipei Veterans General Hospital, TaiwanRecruitingPain, Postoperative | Arthroplasty, Replacement, Knee | Multimodal AnalgesiaTaiwan
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...Trakya University Faculty of MedicineCompletedAnalgesia | Satisfaction, Patient | Vascular Access Complication | Opioid Use, Unspecified | Sedation Complication | RemifentanilTurkey
-
University Hospital, ToulouseRecruitingEpidural Analgesia After Major Open Abdominal SurgeryFrance
-
University GhentEnrolling by invitation
-
Assiut UniversityUnknownPatients Diagnosed With Bipolar Disorder ( Manic Episodes) and Delayed DiagnosisEgypt